BIO Stock 12 Month Analyst Forecast
Consensus Rating
Loading...
Consensus Price Target
Highest Price Target
$481.00
59.52% Upside
Mean Price Target
$346.25
14.83% Upside
Lowest Price Target
$245.00
-18.75% Downside
Recent Analyst Ratings
Upgrades, Downgrades, New Coverage
Actual EPS vs Estimated EPS
BIO Earnings Per Share (EPS) History
According to financial reports, BIO (NYSE: BIO) reported an actual EPS of $2.26 for the quarter ending on Oct 29, 2025, compared to an estimated $2.3, resulting in a -1.74% surprise. In the prior quarter (Jul 31, 2025), BIO recorded an actual EPS of $2.61 with a 35.23% surprise. See BIO's full earnings history.
Earnings History
EPS Surprise Factor Analysis
BIO has experienced notable EPS surprises, with the latest quarter ending Oct 29, 2025 showing a -1.74% miss. Previously, the quarter ending Jul 31, 2025 recorded a 35.23% beat. An EPS surprise factor indicates how much actual earnings deviate from analyst forecasts.
Frequently Asked Questions
Is BIO stock getting favorable reviews from Wall Street analysts?
Brokerage firms have given BIO stock an average recommendation of
Buy. 8 analysts have given their ratings
to BIO out of which
2 analysts have given strong buy call,
2 analysts have given buy call,
4 analysts rate it hold,
0 analysts advocate strong sell call, and
0 analysts has given sell rating. The average target price of
$346.25 gives the stock implied upside
of roughly 14.83% over the next year or so.
What have analysts suggested for BIO highest price target?
Analysts suggest BIO's stock price would rise to a high of $481.00.
What is the lowest price target analysts expect for BIO over the next year?
Within the next 12 months, analysts predict the BIO stock price could move to $245.00.
What is the average target price for BIO?
BIO stock has an average analyst estimate of $346.25.
At its current price, how far is BIO from its average target price?
BIO shares are currently trading 14.83% above this price target.
What were BIO’s actual earnings per share for the recent quarter?
Its quarterly earnings per share (EPS) came in at $2.26 versus consensus estimates of $2.30, and below the comparable year-ago quarter’s EPS of $23.09.
What are the current estimates for quarterly and annual earnings per share?
BIO's forecasts by analysts estimating quarterly EPS at $2.71 and $0.99 for the whole year.
What has BIO's growth been in the past five years and what is expected in the next five years?
The analysts have projected 5.16% EPS growth for BIO in the next five years, compared to growth rates of N/A in the past five years.